New 'Living Drug' trial offers hope for kids with Tough-to-Treat cancer
NCT ID NCT07007117
Summary
This is a first-in-human study to test the safety of a new type of personalized cell therapy called PHOX2B PC-CAR T for patients with advanced, high-risk neuroblastoma that has come back or not responded to other treatments. The main goal is to find the safest and most effective dose by giving the therapy to up to 38 participants and closely monitoring for side effects. The therapy involves collecting a patient's own immune cells, genetically engineering them to target the cancer, and then infusing them back into the patient.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Philadelphia
RECRUITINGPhiladelphia, Pennsylvania, 19104, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.